61.90
11.58%
-8.11
Pre-market:
62.70
0.80
+1.29%
Conmed Corp. stock is currently priced at $61.90, with a 24-hour trading volume of 2.60M.
It has seen a -11.58% decreased in the last 24 hours and a -19.25% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $70.52 pivot point. If it approaches the $67.28 support level, significant changes may occur.
Previous Close:
$70.01
Open:
$63.37
24h Volume:
2.60M
Market Cap:
$1.91B
Revenue:
$1.24B
Net Income/Loss:
$64.46M
P/E Ratio:
33.46
EPS:
1.85
Net Cash Flow:
$106.32M
1W Performance:
-12.92%
1M Performance:
-19.25%
6M Performance:
-32.48%
1Y Performance:
-46.28%
Conmed Corp. Stock (CNMD) Company Profile
Name
Conmed Corp.
Sector
Industry
Phone
315 797 8375
Address
525 French Road, Utica, NY
Conmed Corp. Stock (CNMD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-01-24 | Reiterated | Needham | Buy |
May-22-23 | Initiated | CL King | Buy |
Mar-27-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-21-23 | Initiated | Wells Fargo | Equal Weight |
Oct-12-22 | Initiated | Jefferies | Hold |
Mar-02-22 | Resumed | BofA Securities | Neutral |
Oct-06-21 | Upgrade | Needham | Hold → Buy |
Jul-15-21 | Initiated | UBS | Buy |
May-25-21 | Initiated | Barclays | Overweight |
Nov-26-19 | Downgrade | Needham | Buy → Hold |
Nov-12-19 | Initiated | JP Morgan | Overweight |
Oct-31-19 | Reiterated | Needham | Buy |
Oct-04-19 | Reiterated | Needham | Buy |
Aug-22-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
Apr-18-19 | Initiated | Stifel | Buy |
Apr-16-19 | Reiterated | Needham | Buy |
Jan-23-19 | Reiterated | Needham | Buy |
Oct-16-18 | Initiated | Barclays | Equal Weight |
Aug-07-18 | Reiterated | Needham | Buy |
Aug-02-18 | Reiterated | Needham | Buy |
Apr-26-18 | Reiterated | Needham | Buy |
Feb-01-18 | Reiterated | Needham | Buy |
Jul-27-17 | Reiterated | Needham | Buy |
Apr-27-17 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Apr-27-17 | Reiterated | Needham | Buy |
Nov-18-16 | Reiterated | Needham | Buy |
Jul-28-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Apr-28-16 | Reiterated | Needham | Buy |
Oct-22-15 | Reiterated | Northland Capital | Market Perform |
View All
Conmed Corp. Stock (CNMD) Latest News
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
Zacks Investment Research
Analyst Scoreboard: 5 Ratings For Conmed
Benzinga
Conmed (CNMD) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research
Smith+Nephew (SNN) Expands in Australia With New Alliance
Zacks Investment Research
Here's Why You Should Retain CONMED (CNMD) Stock for Now
Zacks Investment Research
Conmed Corp. Stock (CNMD) Financials Data
Conmed Corp. (CNMD) Revenue 2024
CNMD reported a revenue (TTM) of $1.24 billion for the quarter ending December 31, 2023, a +19.06% rise year-over-year.
Conmed Corp. (CNMD) Net Income 2024
CNMD net income (TTM) was $64.46 million for the quarter ending December 31, 2023, a +179.99% increase year-over-year.
Conmed Corp. (CNMD) Cash Flow 2024
CNMD recorded a free cash flow (TTM) of $106.32 million for the quarter ending December 31, 2023, a +818.10% increase year-over-year.
Conmed Corp. (CNMD) Earnings per Share 2024
CNMD earnings per share (TTM) was $2.04 for the quarter ending December 31, 2023, a +171.83% growth year-over-year.
About Conmed Corp.
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; and endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.
Cap:
|
Volume (24h):